| First Author | Pinto JT | Year | 2014 |
| Journal | J Biol Chem | Volume | 289 |
| Issue | 45 | Pages | 30950-61 |
| PubMed ID | 25231977 | Mgi Jnum | J:218805 |
| Mgi Id | MGI:5618404 | Doi | 10.1074/jbc.M114.591461 |
| Citation | Pinto JT, et al. (2014) Kynurenine aminotransferase III and glutamine transaminase L are identical enzymes that have cysteine S-conjugate beta-lyase activity and can transaminate L-selenomethionine. J Biol Chem 289(45):30950-61 |
| abstractText | Three of the four kynurenine aminotransferases (KAT I, II, and IV) that synthesize kynurenic acid, a neuromodulator, are identical to glutamine transaminase K (GTK), alpha-aminoadipate aminotransferase, and mitochondrial aspartate aminotransferase, respectively. GTK/KAT I and aspartate aminotransferase/KAT IV possess cysteine S-conjugate beta-lyase activity. The gene for the former enzyme, GTK/KAT I, is listed in mammalian genome data banks as CCBL1 (cysteine conjugate beta-lyase 1). Also listed, despite the fact that no beta-lyase activity has been assigned to the encoded protein in the genome data bank, is a CCBL2 (synonym KAT III). We show that human KAT III/CCBL2 possesses cysteine S-conjugate beta-lyase activity, as does mouse KAT II. Thus, depending on the nature of the substrate, all four KATs possess cysteine S-conjugate beta-lyase activity. These present studies show that KAT III and glutamine transaminase L are identical enzymes. This report also shows that KAT I, II, and III differ in their ability to transaminate methyl-L-selenocysteine (MSC) and L-selenomethionine (SM) to beta-methylselenopyruvate (MSP) and alpha-ketomethylselenobutyrate, respectively. Previous studies have identified these seleno-alpha-keto acids as potent histone deacetylase inhibitors. Methylselenol (CH3SeH), also purported to have chemopreventive properties, is the gamma-elimination product of SM and the beta-elimination product of MSC catalyzed by cystathionine gamma-lyase (gamma-cystathionase). KAT I, II, and III, in part, can catalyze beta-elimination reactions with MSC generating CH3SeH. Thus, the anticancer efficacy of MSC and SM will depend, in part, on the endogenous expression of various KAT enzymes and cystathionine gamma-lyase present in target tissue coupled with the ability of cells to synthesize in situ either CH3SeH and/or seleno-keto acid metabolites. |
